Open AccessSPIKE PROTEIN AND ITS PROTEASES ROLE IN SARS-COV-2 PATHOGENICITY AND TREATMENT; A REVIEW
Author(s) -
Fateme Tavakoli Far,
Ehsan AmiriArdekani
Publication year - 2021
Publication title -
pracì naukovogo tovaristva ìmenì ševčenka. medičnì nauki
Language(s) - English
Resource type - Journals
eISSN - 2708-8642
pISSN - 2708-8634
DOI - 10.25040/ntsh2021.01.05
Subject(s) - proteases , coronavirus , virology , biology , virus , pathogenicity , receptor , tmprss2 , renin–angiotensin system , enzyme , genetics , covid-19 , medicine , microbiology and biotechnology , biochemistry , blood pressure , endocrinology , disease , infectious disease (medical specialty)
Since December 2019, a novel beta coronavirus has spread around the world. This virus can cause severe acute respiratory syndrome (SARS). In this study, we reviewed proteases of SARS-CoV-2 based on related articles published in journals indexed by Scopus, PubMed, and Google Scholar from December 2019 to April 2020. Based on this study, we can claim that this coronavirus has about 76% genotype similarity to SARS coronavirus (SARS-CoV). Also, similarities between these two viruses have been found in the mechanism of entry into host cells and pathogenicity. ACE 2, the angiotensin convertase enzyme 2, plays a role in the Renin-Angiotensin-Aldosterone system (RAAS) and blood pressure regulation. Some mechanisms have been reported for the role of ACE 2 in the pathogenicity of SARS-CoV-2. For example, the interaction between the ACE 2 receptor and spike protein mediated by TMPRSS2, Cathepsin B/L, and other enzymes is responsible for the entry of the virus into human cells and pathogenicity. Some host cell endosomal enzymes are necessary to cleavage coronavirus spike protein and cause binding to their common receptor. So, we conclude that molecules like antibodies or small molecules like ACE 2 antagonists and soluble ACE 2 can be used as a good therapeutic candidate to prevent SARS-CoV-2.